News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
602,783 Results
Type
Article (39692)
Company Profile (155)
Press Release (562936)
Section
Business (177508)
Career Advice (2003)
Deals (30914)
Drug Delivery (116)
Drug Development (74538)
Employer Resources (152)
FDA (13199)
Job Trends (13405)
News (302026)
Policy (28319)
Tag
Academia (2282)
Alliances (41280)
Alzheimer's disease (1313)
Approvals (13189)
Artificial intelligence (188)
Bankruptcy (292)
Best Places to Work (10567)
Breast cancer (204)
Cancer (1608)
Cardiovascular disease (136)
Career advice (1659)
Cell therapy (330)
Clinical research (60365)
Collaboration (599)
Compensation (243)
COVID-19 (2197)
C-suite (177)
Data (1574)
Diabetes (220)
Diagnostics (5260)
Earnings (73233)
Employer resources (135)
Events (101848)
Executive appointments (601)
FDA (14014)
Funding (524)
Gene therapy (248)
GLP-1 (696)
Government (3859)
Healthcare (16765)
Infectious disease (2311)
Inflammatory bowel disease (120)
Interviews (318)
IPO (13982)
Job creations (3256)
Job search strategy (1441)
Layoffs (397)
Legal (6595)
Lung cancer (236)
Manufacturing (233)
Medical device (10413)
Medtech (10417)
Mergers & acquisitions (17298)
Metabolic disorders (603)
Neuroscience (1724)
NextGen: Class of 2025 (5769)
Non-profit (4102)
Northern California (1840)
Obesity (332)
Opinion (239)
Patents (163)
People (52831)
Phase I (18779)
Phase II (26261)
Phase III (20259)
Pipeline (758)
Policy (117)
Postmarket research (2402)
Preclinical (7599)
Radiopharmaceuticals (231)
Rare diseases (327)
Real estate (4919)
Regulatory (19531)
Research institute (2023)
Resumes & cover letters (302)
Southern California (1648)
Startups (3032)
United States (16859)
Vaccines (512)
Weight loss (258)
Date
Today (107)
Last 7 days (751)
Last 30 days (2508)
Last 365 days (31402)
2025 (4918)
2024 (32146)
2023 (36231)
2022 (46834)
2021 (50329)
2020 (48141)
2019 (41605)
2018 (31548)
2017 (28975)
2016 (28493)
2015 (33137)
2014 (26051)
2013 (21602)
2012 (23553)
2011 (24233)
2010 (22242)
Location
Africa (714)
Arizona (142)
Asia (36898)
Australia (5556)
California (4219)
Canada (1571)
China (370)
Colorado (206)
Connecticut (198)
Europe (80988)
Florida (647)
Georgia (156)
Illinois (408)
Indiana (262)
Japan (121)
Maryland (653)
Massachusetts (3371)
Michigan (165)
Minnesota (292)
New Jersey (1348)
New York (1277)
North Carolina (847)
Northern California (1840)
Ohio (145)
Pennsylvania (945)
South America (1122)
Southern California (1648)
Texas (623)
Utah (127)
Washington State (409)
602,783 Results for "am pharma holding bv".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
MilliporeSigma Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio
January 7, 2025
·
3 min read
Pharm Country
Amring Pharmaceuticals Inc. Announces Name Change to Nordic Pharma, Inc. Under New Nordic Group, B.V. Ownership
Amring Pharmaceuticals Inc. (“Amring”) announces its name change to Nordic Pharma, Inc. on March 4, 2024, following the change in ownership of the company from SEVER Life Sciences, B.V. to Nordic Group, B.V., a subsidiary of SEVER Life Sciences B.V., which occurred on June 1, 2023.
March 4, 2024
·
3 min read
Press Releases
MilliporeSigma to Acquire HUB Organoids Holding B.V., Advancing Next Generation Biology Portfolio
December 17, 2024
·
5 min read
Press Releases
Zealand Pharma conference call on February 20 at 2pm CET (8am ET) to present full year 2024 financial results
February 14, 2025
·
1 min read
Pharm Country
Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), to Present Data on LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting
Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., will be presenting data on LACRIFILL® Canalicular Gel, a novel therapy for dry eye symptoms, during the American Society of Cataract and Refractive Surgery Annual Meeting in Boston, MA on April 5-8, 2024.
April 2, 2024
·
4 min read
Pharm Country
Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Announces the Launch of LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye.
Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has launched LACRIFILL Canalicular Gel, a novel therapy for dry eye in the U.S. LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.
May 29, 2024
·
3 min read
Drug Development
AM-Pharma Initiates Phase 2 Trial of Ilofotase Alfa for Cardiac Surgery-Associated Renal Damage
AM-Pharma B.V. announced that the first patients have been treated in a Phase 2 clinical study evaluating the company’s proprietary recombinant alkaline phosphatase, ilofotase alfa, as a preventive treatment for cardiac surgery-associated renal damage.
January 16, 2024
·
5 min read
AM-Pharma Announces Updated Clinical Development Strategy
AM-Pharma B.V. announced an updated clinical development strategy to evaluate ilofotase alfa in two indications.
September 26, 2023
·
6 min read
Press Releases
Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Continues Its Introduction of LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, During American Academy of Ophthalmology (AAO) 2024
October 18, 2024
·
4 min read
Deals
Nordic Pharma Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Completes Acquisition of Visant Medical to Launch Novel Therapy for Dry Eye Disease in the United States
Amring Pharmaceuticals Inc. (Amring), a subsidiary of Nordic Group B.V. (Nordic Pharma), announced today the completion of its acquisition of Visant Medical, Inc. (Visant), a leader in medical technology innovation in Dry Eye Disease (DED).
December 18, 2023
·
5 min read
1 of 60,279
Next
